We have created experimental model, which enabled usto solve the following tasks:1. Prostate cancer and benign prostatic hyperplasia tis-sue investigations using infrared light.2. Investigation of infrared light penetration into pros-tate tissue at different modes, which contains 4 subtasks: a)Investigation of infrared light permeability at wavelength, b)Dependence of infrared light penetration on tissue thick-ness, c) Analysis of infrared images of benign prostatic hy-perplasia, d) Analysis of infrared images of prostate cancer.3. Examination of prostate tissues in diffuse mode withinfrared light.4. Examination of prostate tissue in polarized infrared lightmode.5. Preparation of a working model for the examination ofprostate tissues.6. Development of software for processing the receivedinfrared images
Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. New England Journal of Medicine 2001; 344(18):1373–1377.
Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. New England Journal of Medicine 2004; 350(22):2239–2246.
Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 2017; 123(4):592–599.
Faraz A. Baig, Amna Hamid, Talat Mirza, and Serajuddaula Syed. Ductal and Acinar Adenocarcinoma of Prostate: Morphological and Immunohistochemical Characterization, Oman Med J. 2015 May; 30(3): 162-166. doi: 10.5001/ omj.2015.36)
Luechinger, R.; Duru, F.; Candinas, R.; Boesiger, P. (2004). “Safety considerations for magnetic resonance imag- ing of pacemaker and ICD patients”. Herzschrittmacher-therapie und Elektrophysiologie 15: 73. Mikolajczyk SD, Grauer LS, Millar LS, et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology. 1997;50:710–714.